Amber Therapeutics closes $100 million Series A financing led by New Enterprise Associates to advance Amber-UI neuromodulation therapy for mixed urinary incontinence
Amount Raised
$100 Million
Round Type
Series A
LondonBiotechnologyHealth CareTherapeuticsInvestors
Description
Amber Therapeutics, a UK-based medical technology company, has successfully closed its Series A financing round, raising a total of $100 million from leading healthcare and technology investors in the US and UK. The funding will be used to advance Amber-UI, a breakthrough adaptive neuromodulation therapy, towards US FDA approval to treat mixed urinary incontinence (MUI).
Quick answer
Amber Therapeutics raised $100 Million in a Series A round, dated June 10, 2024. Investors: 8VC, Oxford Science Enterprises, Intuitive Ventures, Lightstone Ventures, F Prime Capital and New Enterprise Associates. Amber Therapeutics is based in London, England, United Kingdom.
- How much did Amber Therapeutics raise?
- Amber Therapeutics raised $100 Million in a Series A round on June 10, 2024.
- Who invested in Amber Therapeutics?
- 8VC, Oxford Science Enterprises, Intuitive Ventures, Lightstone Ventures, F Prime Capital and New Enterprise Associates are named as investors in this round.
- What does Amber Therapeutics do?
- Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally transform outcomes in areas of unmet clinical need.
- Where is Amber Therapeutics based and how big is it?
- Amber Therapeutics is based in London, England, United Kingdom.
- Who are the decision-makers at Amber Therapeutics?
- Fundz holds 1 contact at Amber Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Amber Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Pelthos Therapeutics raised $750K on July 24, 2024.
- Autobahn Therapeutics raised $100M (Series C) on July 24, 2024.
- Ensho Therapeutics raised $400K on July 19, 2024.
- GRO Biosciences raised $60M (Series B) on July 19, 2024.
- GRO Biosciences raised $27M on July 18, 2024.
- Renalys Pharma raised $38M (Series A) on July 17, 2024.
Who to call at Amber Therapeutics, and when
A new round usually means Amber Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Amber Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Amber Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Amber Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Amber Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAmber Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.